Insider Shareholders with Direct Ownership of Cyma Bay Therapeutics, Inc. (CBAY)
This section provides a comprehensive overview of the insiders with direct ownership of Cyma Bay Therapeutics, Inc. (CBAY). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
CymaBay Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Dennis D Kim
Chief Medical Officer |
140,100 | 120,100 | 20,000 $0 | 7 |
Apr 17, 2023
Reduced 84.87%
|
| 15,921 | 105,921 | 0 $0 | 3 |
Mar 22, 2024
Reduced 100.0%
|
|
| 0 | 30,000 | 0 $0 | 1 |
Mar 22, 2024
Reduced 100.0%
|
|
|
Paul T Quinlan
General Counsel |
163,262 | 163,262 | 0 $0 | 21 |
Mar 22, 2024
Reduced 100.0%
|
|
Daniel Menold
Vice President, Finance |
119,487 | 52,442 | 0 $0 | 14 |
Jan 16, 2024
Reduced 100.0%
|
|
Klara Dickinson
Chief Regulatory Officer |
21,000 | 21,000 | 0 $0 | 2 |
Mar 22, 2024
Reduced 100.0%
|
|
Charles Mc Wherter
President of R&D |
203,497 | 218,497 | 0 $0 | 20 |
Mar 22, 2024
Reduced 100.0%
|
|
Sujal Shah
Chief Executive Officer |
481,259 | 601,259 | 0 $0 | 10 |
Mar 22, 2024
Reduced 100.0%
|
| 25,000 | 25,000 | 0 $0 | 8 |
Feb 12, 2024
Reduced 100.0%
|
|
|
Harish Shantharam
Chief Financial Officer |
20,125 | 20,125 | 0 $0 | 2 |
Mar 22, 2024
Reduced 100.0%
|